Zobrazeno 1 - 10
of 354
pro vyhledávání: '"Fumio Imazeki"'
Autor:
Shingo Nakamoto, Fumio Imazeki, Makoto Arai, Shin Yasui, Masato Nakamura, Yuki Haga, Reina Sasaki, Tatsuo Kanda, Hiroshi Shirasawa, Osamu Yokosuka
Publikováno v:
International Journal of Molecular Sciences, Vol 16, Iss 9, Pp 21177-21190 (2015)
We examined whether hepatitis C virus (HCV) genotype 1b core- and NS5A-region mutations are associated with response to peginterferon α-2b plus ribavirin combination therapy. A total of 103 patients with high HCV genotype 1b viral loads (≥100 KIU/
Externí odkaz:
https://doaj.org/article/dbd421fca73d454d91f7aac73e9bb829
Autor:
Tatsuo Kanda, Masato Nakamura, Reina Sasaki, Shin Yasui, Shingo Nakamoto, Yuki Haga, Xia Jiang, Shuang Wu, Akinobu Tawada, Makoto Arai, Fumio Imazeki, Osamu Yokosuka
Publikováno v:
Case Reports in Gastroenterology, Vol 9, Iss 2, Pp 215-220 (2015)
Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasi
Externí odkaz:
https://doaj.org/article/c00a0bc6bddc4d0c9713b57bf571e7e6
Autor:
Shingo Nakamoto, Tatsuo Kanda, Chiaki Nakaseko, Emiko Sakaida, Chikako Ohwada, Masahiro Takeuchi, Yusuke Takeda, Naoya Mimura, Tohru Iseki, Shuang Wu, Makoto Arai, Fumio Imazeki, Kengo Saito, Hiroshi Shirasawa, Osamu Yokosuka
Publikováno v:
International Journal of Molecular Sciences, Vol 15, Iss 11, Pp 21455-21467 (2014)
We retrospectively reviewed 413 recipients with hematologic malignancies who underwent hematopoietic stem cell transplantation (HSCT) between June 1986 and March 2013. Recipients with antibody to hepatitis B core antigen (anti-HBc) and/or to hepatiti
Externí odkaz:
https://doaj.org/article/1028f3ab795a466abdd4236d0376f023
Autor:
Tatsuo Kanda, Shingo Nakamoto, Shin Yasui, Masato Nakamura, Tatsuo Miyamura, Shuang Wu, Xia Jiang, Makoto Arai, Fumio Imazeki, Osamu Yokosuka
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 2, Pp 288-296 (2014)
The use of phlebotomy is relatively common for ‘difficult-to-treat by antiviral therapies' hepatitis C virus (HCV)-infected patients and for certain patients having chronic liver diseases with an iron overload of the liver. In the present study, we
Externí odkaz:
https://doaj.org/article/98fe58a014b54c80a49960c8d7a0cf3a
Autor:
Masahiro Hayashi, Tatsuo Kanda, Masato Nakamura, Tatsuo Miyamura, Shin Yasui, Shingo Nakamoto, Shuang Wu, Makoto Arai, Fumio Imazeki, Osamu Yokosuka
Publikováno v:
Case Reports in Gastroenterology, Vol 8, Iss 1, Pp 129-133 (2014)
Some patients with alcohol dependence may initially present with atypical laboratory and histological features resembling autoimmune hepatitis (AIH) or drug-induced liver injury (DILI). Even with liver biopsy, it may be difficult to diagnose certain
Externí odkaz:
https://doaj.org/article/e511d258c69c4b05b441da4700bc8bb6
Autor:
Osamu Yokosuka, Fumio Imazeki, Makoto Arai, Keiichi Fujiwara, Xia Jiang, Shuang Wu, Shingo Nakamoto, Tatsuo Kanda, Tatsuo Miyamura
Publikováno v:
Viruses, Vol 4, Iss 8, Pp 1264-1278 (2012)
It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment
Externí odkaz:
https://doaj.org/article/d0e0c0ee0f0b405f94eac7de349558fc
Autor:
Toru Wakamatsu, Tatsuo Kanda, Akinobu Tawada, Tatsuo Miyamura, Masanori Takahashi, Tetsuhiro Chiba, Makoto Arai, Hitoshi Maruyama, Keiichi Fujiwara, Fumio Imazeki, Osamu Yokosuka
Publikováno v:
Case Reports in Gastroenterology, Vol 6, Iss 2, Pp 394-399 (2012)
Antimitochondrial antibody (AMA) is one of the representative features of primary biliary cirrhosis (PBC). PBC is a female-dominant disease usually presenting intrahepatic bile duct destruction, cholestasis and fibrosis with or without chronic nonsup
Externí odkaz:
https://doaj.org/article/4323eb66abaa4acc8a73ce5742a4cabb
Autor:
Tatsuo Kanda, Masato Nakamura, Shin Yasui, Yuki Haga, Akinobu Tawada, Eiichiro Suzuki, Yoshihiko Ooka, Koji Takahashi, Reina Sasaki, Shuang Wu, Shingo Nakamoto, Makoto Arai, Fumio Imazeki, Osamu Yokosuka
Publikováno v:
Biology, Vol 6, Iss 2, p 30 (2017)
The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT
Externí odkaz:
https://doaj.org/article/9ad01998a3454dbdbbc098718bc18528
Autor:
Nan Nwe Win, Shingo Nakamoto, Tatsuo Kanda, Hiroki Takahashi, Azusa Takahashi-Nakaguchi, Shin Yasui, Masato Nakamura, Shuang Wu, Fumio Imazeki, Shigeru Mikami, Osamu Yokosuka, Tohru Gonoi, Hiroshi Shirasawa
Publikováno v:
International Journal of Molecular Sciences, Vol 18, Iss 1, p 172 (2017)
Determination of hepatitis C virus (HCV) genotypes plays an important role in the direct-acting agent era. Discrepancies between HCV genotyping and serotyping assays are occasionally observed. Eighteen samples with discrepant results between genotypi
Externí odkaz:
https://doaj.org/article/bd2d68e2f7784ad8a109fc2e3f48d87d
Autor:
Tatsuo Miyamura, Tatsuo Kanda, Shingo Nakamoto, Makoto Arai, Masato Nakamura, Shuang Wu, Xia Jiang, Reina Sasaki, Yuki Haga, Shin Yasui, Yoshihiko Ooka, Tetsuhiro Chiba, Fumio Imazeki, Shigeru Mikami, Osamu Yokosuka
Publikováno v:
International Journal of Hepatology, Vol 2014 (2014)
Aim. Eradication of hepatitis C virus (HCV) is still challenging even if interferon- (IFN-) free regimens with direct-acting antiviral agents (DAAs) for HCV-infected individuals are available in clinical practice. IFNL4 is a newly described protein,
Externí odkaz:
https://doaj.org/article/1beabe62777a45b1ababe7660102547d